Nash

Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020

Retrieved on: 
Monday, November 9, 2020
Oncology, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Hepatitis, Clinical medicine, Anatomy, Non-alcoholic fatty liver disease, Steatohepatitis, Fatty liver disease, Liver disease, Nash, Alcoholic liver disease

Dr. Fishmans chat will focus on Can-Fites Namodenoson in the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

Key Points: 
  • Dr. Fishmans chat will focus on Can-Fites Namodenoson in the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
  • The NASH market is projected to reach at least $35 billion by 2025.
  • There are currently no other treatment options approved for this growing unmet need.
  • Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Reliability of Liver Biopsies in NASH Clinical Studies: What is Known So Far? What's Next? Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Friday, October 23, 2020
Medical specialties, Clinical medicine, Medicine, Hepatology, Non-alcoholic fatty liver disease, Steatohepatitis, Liver biopsy, Nash, Liver, Hepatitis, Biopsy, Alcoholic liver disease

TORONTO, Oct. 23, 2020 /PRNewswire-PRWeb/ --Liver biopsy (LB) sample evaluation is an essential part of clinical studies in non-alcoholic steatohepatitis (NASH).

Key Points: 
  • TORONTO, Oct. 23, 2020 /PRNewswire-PRWeb/ --Liver biopsy (LB) sample evaluation is an essential part of clinical studies in non-alcoholic steatohepatitis (NASH).
  • Histologic lesions of NASH are unevenly distributed throughout the liver parenchyma.
  • For more information or to register for this event, visit Reliability of Liver Biopsies in NASH Clinical Studies: What is Known So Far?
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

Harvey Nash Group becomes a major force in US technology recruitment

Retrieved on: 
Thursday, October 22, 2020
Harvey Nash, Nash

LONDON, Oct. 22, 2020 /PRNewswire/ -- Harvey Nash Group, the global technology recruitment and solutions Group, has acquired Latitude 36 as part of its strategic expansion in the U.S., the world's largest and most dynamic recruitment market.

Key Points: 
  • LONDON, Oct. 22, 2020 /PRNewswire/ -- Harvey Nash Group, the global technology recruitment and solutions Group, has acquired Latitude 36 as part of its strategic expansion in the U.S., the world's largest and most dynamic recruitment market.
  • Jason Allen, CEO of Harvey NashTechnology Recruitmentdivision Northern Europe, Australia and US, commented: "I am extremely excited about Latitude 36 joining the Harvey Nash Group family.
  • Jason Pyle, President & COO of Latitude 36, commented: "We are thrilled and excited to become part of the Harvey Nash Group.
  • Blackwood Capital Group acted as M&A advisor to Harvey Nash on this transaction.Ronny Grosman, Managing Partner of Blackwood Capital: "We are incredibly proud and pleased to have advised Harvey Nash on this landmark transaction.

Harvey Nash Group becomes a major force in US technology recruitment

Retrieved on: 
Thursday, October 22, 2020
Harvey Nash, Nash

LONDON, Oct. 22, 2020 /PRNewswire/ -- Harvey Nash Group, the global technology recruitment and solutions Group, has acquired Latitude 36 as part of its strategic expansion in the U.S., the world's largest and most dynamic recruitment market.

Key Points: 
  • LONDON, Oct. 22, 2020 /PRNewswire/ -- Harvey Nash Group, the global technology recruitment and solutions Group, has acquired Latitude 36 as part of its strategic expansion in the U.S., the world's largest and most dynamic recruitment market.
  • Jason Allen, CEO of Harvey NashTechnology Recruitmentdivision Northern Europe, Australia and US, commented: "I am extremely excited about Latitude 36 joining the Harvey Nash Group family.
  • Jason Pyle, President & COO of Latitude 36, commented: "We are thrilled and excited to become part of the Harvey Nash Group.
  • Blackwood Capital Group acted as M&A advisor to Harvey Nash on this transaction.Ronny Grosman, Managing Partner of Blackwood Capital: "We are incredibly proud and pleased to have advised Harvey Nash on this landmark transaction.

Akero Therapeutics To Present Data From Phase 2a BALANCED Study Of Efruxifermin In NASH Patients In Presidential Plenary Talk At The Liver Meeting® 2020

Retrieved on: 
Friday, October 2, 2020
Medical specialties, Clinical medicine, Anatomy, RTT, Non-alcoholic fatty liver disease, Steatohepatitis, Fatty liver disease, FGF21, Hepatitis, Nash, Liver disease, Liver

Abstract Title: Efruxifermin (EFX), a long-acting Fc-FGF21 fusion protein, administered for 16 weeks to patients with NASH substantially reduces liver fat and ALT, and improves liver histology: analysis of a randomized, placebo-controlled, Phase 2a study (BALANCED).

Key Points: 
  • Abstract Title: Efruxifermin (EFX), a long-acting Fc-FGF21 fusion protein, administered for 16 weeks to patients with NASH substantially reduces liver fat and ALT, and improves liver histology: analysis of a randomized, placebo-controlled, Phase 2a study (BALANCED).
  • NASH (non-alcoholic steatohepatitis) is a serious form of NAFLD (non-alcoholic fatty liver disease) and is estimated to affect 17 million Americans.
  • Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemicby developing pioneering medicines designed torestore metabolic balance and improve overall health of NASH patients.
  • The Company's lead product candidate, efruxifermin, has been evaluated in a 16-week Phase 2a clinical trial, the BALANCED study.

Metacrine to Present New Data from MET409 Program in NASH at AASLD’s The Liver Meeting Digital Experience™

Retrieved on: 
Thursday, October 1, 2020
Medical specialties, Hepatitis, Clinical medicine, Chemical compounds, RTT, Non-alcoholic fatty liver disease, Steatohepatitis, Nash, Carboxylic acids, Tropifexor

Combined with a favorable pharmacological and tolerability profile, these results further highlight the therapeutic potential of MET409 for patients with NASH.

Key Points: 
  • Combined with a favorable pharmacological and tolerability profile, these results further highlight the therapeutic potential of MET409 for patients with NASH.
  • We look forward to presenting these data, which support the continued advancement of our FXR program, including both MET409 and our second clinical candidate, MET642.
  • These results demonstrate robust, sustained FXR activation by MET409 and correlate with previously-reported benefits of LFC reduction and improvement in liver chemistries.
  • Both MET409 and MET642 are currently being investigated in clinical trials as potential new treatments for non-alcoholic steatohepatitis (NASH).

HighTide Therapeutics to Present at HC Wainwright’s 4th Annual NASH Investor Conference

Retrieved on: 
Thursday, October 1, 2020
Biotechnology, Medical devices, Other Health, Health, Pharmaceutical, Medical specialties, Clinical medicine, Medicine, RTT, Steatohepatitis, Non-alcoholic fatty liver disease, Gastrointestinal disease, Nash, Liver disease, Hepatitis

HighTide Therapeutics Inc. (HighTide), a clinical-stage biopharmaceutical company with novel treatments for patients with non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that Liping Liu, Founder and Chief Executive Officer, and Adrian M. Di Bisceglie, Chief Medical Officer, will present virtually at the HC Wainwright 4th Annual NASH Conference on Monday, October 5, 2020 at 9:30am EDT.

Key Points: 
  • HighTide Therapeutics Inc. (HighTide), a clinical-stage biopharmaceutical company with novel treatments for patients with non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that Liping Liu, Founder and Chief Executive Officer, and Adrian M. Di Bisceglie, Chief Medical Officer, will present virtually at the HC Wainwright 4th Annual NASH Conference on Monday, October 5, 2020 at 9:30am EDT.
  • HighTide Therapeutics Inc. is dedicated to the development of innovative therapeutics for people suffering from non-viral chronic liver diseases, gastrointestinal diseases and metabolic disorders with large and unmet medical needs.
  • HTD1801 is a new molecular entity being developed for the treatment of NASH and PSC.
  • HTD1801 has received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC.

Company Profile for Axcella Health Inc.

Retrieved on: 
Thursday, September 24, 2020
Health, Biotechnology, Medical specialties, Clinical medicine, Hepatitis, RTT, Hepatology, Steatohepatitis, Non-alcoholic fatty liver disease, Hepatic encephalopathy, Nash, EMMS, EMMS

Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health.

Key Points: 
  • Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health.
  • The companys product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways.
  • Axcellas pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence.
  • Additional muscle- and blood-related programs are in earlier-stage development.

Poxel Reports Financial Results for First Half 2020 and Provides a Corporate Update

Retrieved on: 
Tuesday, September 15, 2020
Health, Diabetes, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Hepatitis, Clinical medicine, Non-alcoholic fatty liver disease, Steatohepatitis, Nash

POXEL SA (Euronext POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today reported its financial results for the period ended June 30, 2020 and provided a corporate update.

Key Points: 
  • POXEL SA (Euronext POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today reported its financial results for the period ended June 30, 2020 and provided a corporate update.
  • Efficacy and safety results from the Phase 2a trial in approximately 100 likely-NASH patients are currently expected around the end of September 2020.
  • Poxel anticipates presenting results for PXL065 at the AASLD meeting and publishing data in scientific journals during the second half of 2020.
  • Poxel reported revenues of EUR 6.4 million for the six months ended June 30, 2020, as compared to EUR 23.2 million during the corresponding period in 2019 (historical).

Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist

Retrieved on: 
Monday, September 14, 2020
Drug Safety, Food and Drug Administration, Hepatitis, Health, Medical specialties, Pharmaceutical industry, Steatohepatitis, New Drug Application, Investigational New Drug, Nash, Non-alcoholic fatty liver disease

SHANGHAI, Sept. 13, 2020 /PRNewswire/ --Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672)announces today that it has filed investigational new drug application (IND) with US FDA for its non-alcoholic steatohepatitis (NASH) drug candidate ASC42.

Key Points: 
  • SHANGHAI, Sept. 13, 2020 /PRNewswire/ --Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672)announces today that it has filed investigational new drug application (IND) with US FDA for its non-alcoholic steatohepatitis (NASH) drug candidate ASC42.
  • Gannex has two additional drug candidates at clinical stage in its NASH pipeline, ASC40 and ASC41.
  • ASC41 is an oral thyroid hormone receptor beta (THR-beta) agonist which recently received IND approval from China's National Medical Products Administration (NMPA) to conduct clinical trials for NASH indication.
  • NASH: global development of novel drug candidates against three different targets FASN, THR-beta and FXR, which are expected to be used alone or in combination.